In one paragraphArticle in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors.
Davide SoldatoDavide Soldato, MD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Ines Vaz-Luis, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France, Supportive Care and Pathways Department (DIOPP), Gustave Roussy, Villejuif, France; Antonio Di Meglio, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Lee W. Jones, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Weill Cornell Medical College, New York, NY; and Stefan Michiels, PhD, INSERM U1018 CESP, Service de Biostatistique et d'Epidemiologie, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-2090-3245 Ines Vaz-LuisDavide Soldato, MD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Ines Vaz-Luis, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France, Supportive Care and Pathways Department (DIOPP), Gustave Roussy, Villejuif, France; Antonio Di Meglio, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Lee W. Jones, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Weill Cornell Medical College, New York, NY; and Stefan Michiels, PhD, INSERM U1018 CESP, Service de Biostatistique et d'Epidemiologie, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-7194-2260 Antonio Di MeglioDavide Soldato, MD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Ines Vaz-Luis, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France, Supportive Care and Pathways Department (DIOPP), Gustave Roussy, Villejuif, France; Antonio Di Meglio, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Lee W. Jones, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Weill Cornell Medical College, New York, NY; and Stefan Michiels, PhD, INSERM U1018 CESP, Service de Biostatistique et d'Epidemiologie, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-0233-3189 Lee W JonesDavide Soldato, MD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Ines Vaz-Luis, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France, Supportive Care and Pathways Department (DIOPP), Gustave Roussy, Villejuif, France; Antonio Di Meglio, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Lee W. Jones, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Weill Cornell Medical College, New York, NY; and Stefan Michiels, PhD, INSERM U1018 CESP, Service de Biostatistique et d'Epidemiologie, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-3716-8793 Stefan MichielsDavide Soldato, MD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Ines Vaz-Luis, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France, Supportive Care and Pathways Department (DIOPP), Gustave Roussy, Villejuif, France; Antonio Di Meglio, MD, PhD, INSERM U981-Prédicteurs moléculaires et nouvelles cibles en oncologie, Gustave Roussy, Villejuif, France; Lee W. Jones, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, Weill Cornell Medical College, New York, NY; and Stefan Michiels, PhD, INSERM U1018 CESP, Service de Biostatistique et d'Epidemiologie, Institut Gustave Roussy, Villejuif, France.ORCID 0000-0002-6963-2968 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID39303199
PMCPMC11652231
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390